Investment Trends in Immuno-Oncology

Summary:In this podcast, recorded at the February 2024 IO360º summit, biopharma, finance and investment experts discuss the fundability features of IO biotechs, and the current pharma needs that will drive potential partnerships or M&A. Moderater:Axel Hoos, MD, PhD, Former CEO, Scorpion TherapeuticsPanelists: Irina Margine, PhD, Principal, Biotech Private Equity, Wellington ManagementKhalil Barrage, Managing Partner, Invus GroupJeffrey Bockman, PhD, EVP, Oncology and Virology Practices, LumanityEmmett Schmidt, MD, PhD, VP, Clinical Oncology, External Collaborations, MerckGayatri Varma, PhD, Executive Director and Head of Transactions, Oncology R&D, AstraZenecaFor more information, go to IO360summit.com.